Bill > S1681

This bill aims to educate healthcare providers and the public on biosimilar biological products, which are similar but not identical to reference biological products. The key provisions include: 1. The Secretary of Health and Human Services may maintain a website to provide educational materials on the meaning of terms like "biosimilar" and "interchangeable," the standards for review and licensing of biological products, information on development programs, and guidance on reporting adverse events. 2. The educational materials may be provided in various formats like webinars, videos, and fact sheets, tailored to the unique needs of healthcare providers, patients, and caregivers. 3. The Secretary is also required to advance education and awareness among healthcare providers on the prescribing and relevant clinical considerations for biological products, including biosimilars and interchangeable biosimilars. The overall goal is to increase understanding and adoption of biosimilar and interchangeable biological products, which can help improve access to these potentially more affordable treatments.